Shanghai Fosun Pharmaceutical Schedules Board Meeting for Q3 Results
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Shanghai...
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them